Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 3.24
Day High 3.36
Open:3.28
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Resverlogix Corp is a clinical stage biotechnology company. It is engaged in developing RVX-208, a molecule selective inhibit BET domain inhibitor for the treatment of patients with cardiovascular, diabetes mellitus, Alzheimer's & chronic kidney disease.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Resverlogix Presents at Clinical Trials in Alzheimer's Disease (CTAD) Asia 2018
GlobeNewswire - Tue Sep 4, 7:01AM CDT
GlobeNewswire - CMTX
Tue Sep 4, 7:01AM CDT
As a follow up to its July 17, 2018 news release, Resverlogix Corp. ("Resverlogix" or the "Company") (RVX:TSX) announced today that it has presented at the first Clinical Trials in Alzheimer's Disease (CTAD) Asia conference in Shanghai, China, this past weekend. Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center, Las Vegas, Nevada, delivered a keynote presentation on the design and baseline characteristics of a pre-specified substudy of cognition in elderly patients in the Company's ongoing Phase 3 BETonMACE clinical trial. In addition, a poster presentation highlighted potential Mechanism of Action of apabetalone in addressing vascular dementia.
Resverlogix Announces $26 Million Private Placement
GlobeNewswire - Thu Aug 30, 7:01AM CDT
GlobeNewswire - CMTX
Thu Aug 30, 7:01AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of approximately 10.4 million equity units at a price of $2.50 per unit for gross proceeds of approximately $26 million (US$20 million), based on an agreed discount to the 5-day volume weighted average price of the Company's shares between July 30 and August 3, 2018. Each unit will be comprised of one common share and one-half (1/2) of a common share purchase warrant. Each full warrant will be exercisable at a price of $3.00 per share for a period of three years from the closing of the private placement. The units will be subject to a four-month hold period.
Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich
GlobeNewswire - Wed Aug 22, 6:00AM CDT
GlobeNewswire - CMTX
Wed Aug 22, 6:00AM CDT
Key Opinion Leaders gather to discuss: LDL-c: Done Deal, Next Epigenetics?
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.90 +12.07% increase
on 09/25/18
Period Open:3.64
Price movement based on the high, low and last over the given period.
3.80 -14.47% decrease
on 10/09/18
-0.39 (-10.71%) decrease
since 09/19/18
3-Month 2.27 +43.17% increase
on 07/20/18
Period Open:2.29
Price movement based on the high, low and last over the given period.
4.31 -24.59% decrease
on 09/07/18
+0.96 (+41.92%) increase
since 07/19/18
52-Week 1.11 +192.79% increase
on 05/31/18
Period Open:1.43
Price movement based on the high, low and last over the given period.
4.31 -24.59% decrease
on 09/07/18
+1.82 (+127.27%) increase
since 10/19/17

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement